Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Raw Materials data on file, last reported at $21.9 million in Q1 2026.

• On a quarterly basis, Raw Materials rose 18.9% year-over-year to $21.9 million in Q1 2026; TTM through Mar 2026 was $21.9 million, a 18.9% increase from a year earlier, with the FY2025 full-year figure at $21.9 million, down 8.94% from the prior year.
• Raw Materials for Q1 2026 stood at $21.9 million, roughly flat from $21.9 million in the prior quarter.
• Over the last five years, Raw Materials for HALO reached as high as $30.6 million in Q3 2024 and fell as low as $10.2 million in Q2 2022.
• Historically, Raw Materials has averaged $20.8 million across 5 years, with a median of $21.9 million in 2026.
• Across the five-year window, Raw Materials soared 137.5% in 2023 and tumbled 37.99% in 2025, its largest moves.
• Year by year, Raw Materials stood at $13.8 million in 2022, then jumped by 71.45% to $23.6 million in 2023, then advanced by 1.56% to $24.0 million in 2024, then declined by 8.94% to $21.9 million in 2025, then gained by 0.15% to $21.9 million in 2026.
• Per Business Quant data, the three most recent Raw Materials figures were $21.9 million in Q1 2026, $21.9 million in Q4 2025, and $19.0 million in Q3 2025.